• br Concluding remarks Following the disappointing outcomes o

  2023-06-19

  

  Concluding remarks Following the disappointing outcomes of Aβ immunotherapy trials for AD [62], the current prevailing concept is that disease-modifying therapy must be initiated from the presymptomatic stage of the disease because of the presumed incurability of chronic diseases once they become

• br Concluding remarks Following the disappointing outcomes o

  2023-06-19

  

  Concluding remarks Following the disappointing outcomes of Aβ immunotherapy trials for AD [62], the current prevailing concept is that disease-modifying therapy must be initiated from the presymptomatic stage of the disease because of the presumed incurability of chronic diseases once they become

• Changes in actin microfilaments are mediated by

  2023-06-16

  

  Changes in S1RA microfilaments are mediated by changes in extracellular matrix, mechanical stimulation or growth factors intracellular signaling. We observed significant changes in a number of intracellular signaling pathways associated with changes in actin dynamics during hMSCs differentiation. D

• The AAP s policy statement on

  2023-06-15

  

  The AAP’s policy statement on childhood adversities is a call to the pediatric Butaprost to apply the knowledge toward developmental screening in clinical practice. It is a movement to increase education around childhood adversity as a public health crisis and to build trauma-informed care into ped

• br LOX in colorectal cancer Colorectal cancer CRC

  2023-06-14

  

  5-LOX in colorectal cancer Colorectal cancer (CRC) like other malignancies exhibits an overexpression of 5-LOX. Ohd et al. (Ohd et al., 2003) revealed in a study that malignant colon tissues overexpress 5-LOX activity and retain elevated levels of inflammatory mediators, leukotrienes. Additionall

• br Special report Financial and personal

  2023-06-03

  

  Special report – Financial and personal benefits of early diagnosis Acknowledgments The Alzheimer’s Association acknowledges the contributions of Joseph Gaugler, Ph.D., Bryan James, Ph.D., Tricia Johnson, Ph.D., Allison Marin, Ph.D., and Jennifer Weuve, M.P.H., Sc.D., in the preparation of 201

• Compounds were profiled for their inhibitory

  2023-05-30

  

  Compounds – were profiled for their inhibitory activity against dipeptidyl peptidase-IV Activity and/or Structure Homologues (DASH) [e.g. DPP2, DPP8 and DPP9] and non-DASH [eg. post-proline cleaving enzyme (PPCE), neutral endopeptidase (NEP), aminopeptidase P (APP), aminopeptidase N (APN)] enzymes.

• br AD and COX LOX pharmacology

  2023-05-30

  

  AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re

• br Concluding Remarks and Future Directions The physiologica

  2023-05-30

  

  Concluding Remarks and Future Directions The physiological significance of autophagy in neuronal function is steadily emerging. The studies discussed herein reveal that key neuronal functions, such as neurotransmitter release, pruning of dendritic spines, and behavioural outputs of neural network

• Elevated expression of Aurora A and

  2023-05-30

  

  Elevated expression of Aurora-A and -B frequently detected in a wide variety of human cancers strongly indicate that high expression of these kinases play roles in the development of cancer associated phenotypes. While Aurora-A has been shown to function as an oncogene when over expressed in mammali

• Prote Our data indicate that the D domain only needs to

  2023-05-30

  

  Our data indicate that the D1 domain only needs to hydrolyze ATP a few times, or perhaps even just once, during the processing of a given substrate molecule, whereas the D2 domain hydrolyzes ATP many times. Consistent with this model, only D2 contains the canonical aromatic pore loop residues implic

• It is worth noting that

  2023-05-29

  

  It is worth noting that in S. cerevisiae, the control of two cell-cycle checkpoints requiring Mcm1 involves two very different mechanisms. At the G1/S transition, Mcm1 transactivation activity is inhibited by Yox1 and Yhp1 repressors, whose expression is periodically regulated through the cell cycle

• Immunohistochemistry in tissue samples showed the expression

  2023-05-29

  

  Immunohistochemistry in tissue samples showed the expression of several nuclear receptor co-activators, including NCOA1, NCOA2, NCOA3, CREBBP, and EP300, in 85–100% of ODQ tumors even some of which lacked AR expression (Boorjian et al., 2009). Knockdown of each co-activator also resulted in signifi

• The increased occurrence of ARIA E in APOE carriers in

  2023-05-29

  

  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied

• br Stress glucocorticoids as risk factor

  2023-05-29

  

  Stress/glucocorticoids as risk factor for Alzheimer’s Disease: preclinical studies A role for glucocorticoids in shaping the risk for AD is supported by animal studies using rats or mice injected with Aβ oligomers, tau protein or excitotoxins, or transgenic (Tg) mice carrying mutations associated

15874 records 297/1059 page Previous Next First page 上5页 296297298299300 下5页 Last page